Trial · NCT01876251
Results by group237
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 237
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1 | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | 1 | participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | 1 | participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | 4 | participants | ||
| Progression-free Survival (PFS) at 6 Months - Expansion Cohort | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | 4.1 | 95% Confidence Interval 1.3 to 8.1 | months | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | All causality TEAEs | 15 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | All causality TEAEs | 3 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | All causality TEAEs | 11 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | Treatment-related (TR) TEAEs | 15 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | Treatment-related (TR) TEAEs | 3 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | Treatment-related (TR) TEAEs | 11 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | All causality SAEs | 4 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | All causality SAEs | 3 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | All causality SAEs | 6 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | TR SAEs | 3 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | TR SAEs | 3 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | TR SAEs | 6 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | Grade 3 or 4 TEAEs, all causality | 15 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | Grade 3 or 4 TEAEs, all causality | 3 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | Grade 3 or 4 TEAEs, all causality | 11 | participants | |
| Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | Grade 3 or 4 TEAEs, TR | 15 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01876251/results